▮ DFV TERMINAL
--:--:-- UTC SIGN IN
F1 Terminal / LH

LH — LABCORP HOLDINGS INC.

—
NYSE · Health Care · Health Care Providers & Services · CIK 920148 ·
Last close
$265.03
Market Cap
$21.73B
52W High
$278.94
52W Low
$247.91
ADV30
612,320
Next earnings
2026-07-23
Labcorp Holdings Inc. provides laboratory services. It operates through two segments, Diagnostics Laboratories and Biopharma Laboratory Services. The company offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, PAP tests, hemoglobin A1C, PSA, tests for sexually transmitted diseases, vitamin D testing, microbiology cultures and procedures, and alcohol and other substance abuse tests. It also provides specialty testing services comprising gene-based and esoteric testing; advanced tests target specific diseases; services related to anatomic pathology/oncology, cardiovascular disease, coagulation, diagnostic genetics, endocrinology, infectious disease, women's health, pharmacogenetics, parentage and donor testing, occupational testing services, medical drug monitoring services, chronic disease programs, and kidney stone prevention tests; and health and wellness services to employers and managed care organizations. In addition, the company offers digital pathology solutions, a pathology platforms that support the digitization, centralized review, and sharing of pathology slides; provider and payer digital platforms, an online applications for providers, MCOs, and ACOs; online and mobile applications that enable patients to check offerings, schedule PSC visits, check-in upon PSC arrival, complete documentation, access tests and test results, and manage their accounts; and Generative AI-enabled Test Selection, a generative AI-enabled tool. It serves clients, third party, medicare/medicaid, patients, pharmaceutical, biotechnology, medical device, diagnostic companies, and CROs. The company has a strategic collaboration with the Children's Hospital of Philadelphia to accelerate the discovery, development, and availability of pediatric diagnostics. It also has a collaboration with Alliance for Clinical Trials in Oncology to advance national clinical trial for patients diagnosed with colorectal cancer. The company was founded in 1995 and is headquartered in Burlington, North Carolina.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Mar 2026 3,537,600,000 1,013,800,000 387,200,000 277,800,000 19,087,100,000 981,100,000 10,341,600,000
Dec 2025 3,515,800,000 993,200,000 382,000,000 164,700,000 18,392,700,000 532,300,000 9,756,000,000
Sep 2025 3,563,500,000 1,025,100,000 403,200,000 261,100,000 18,261,600,000 598,100,000 9,548,600,000
Jun 2025 3,527,300,000 1,046,200,000 398,600,000 237,900,000 18,059,900,000 647,300,000 9,570,500,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$1,813,500,000
Investing CF
$-1,180,100,000
Financing CF
$-36,800,000
CapEx
$-429,500,000
Dividends Paid
$-240,300,000
Buybacks
$-548,000,000
EPS Diluted TTM
$11.29
As of
2026-05-10

Balance + Analyst (yfinance extras)

Retained Earnings
$8,784,400,000
Inventory
$497,700,000
Receivables
$2,450,500,000
ST Investments
—
EBIT TTM
$1,375,200,000
Pretax Income TTM
$1,152,000,000
Interest Exp TTM
$223,200,000
Analysts
17

Yahoo Snapshot (yfinance, live)

Total Revenue
$14,144,199,680
EBITDA
$2,252,999,936
Free Cash Flow
$1,142,537,472
Enterprise Value
$28,062,660,608
Total Cash
$981,100,032
Total Debt
$7,294,400,000
Shares Out
82,000,000
Trailing EPS
$11.29
Book Value
$106.06
ROE
11.0%
ROA
5.3%
Div Yield
1.09%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 13,951,700,000 1,516,200,000 876,500,000 18,392,700,000 9,756,000,000 — 1,640,500,000
Dec 2024 13,008,900,000 1,138,000,000 746,000,000 18,379,000,000 10,312,500,000 — 1,585,800,000
Dec 2023 12,161,600,000 1,123,700,000 418,000,000 16,725,100,000 8,834,600,000 — 1,327,700,000
Dec 2022 11,863,900,000 1,752,200,000 1,279,100,000 20,155,100,000 10,039,600,000 — 1,955,900,000

TTM Snapshot

Revenues TTM
$13,268,200,000
NetIncome TTM
$1,292,700,000
OpCashFlow TTM
$0
Assets (Latest)
$18,379,000,000
Forward EPS
$19.44

Max Pain — expiry 2026-06-18

max pain strike: $260.00 · spot: $264.76 · call oi: 421 · put oi: 1,141
Expected Move to 2026-06-18: ±$6.52 (2.46%) — implied range $258.24 – $271.29 · ATM straddle on $260.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
DGX QUEST DIAGNOSTICS INC $22.38B $202.18 —
GH Guardant Health, Inc. $17.21B $129.82 —
THC TENET HEALTHCARE CORP $15.43B $179.11 —
NTRA Natera, Inc. $31.07B $216.97 —
DVA DAVITA INC. $13.46B $209.75 —

News headlines (Yahoo Finance, 1h cache)

LH vs. CRL: Which Stock Is the Better Value Option?
2026-06-15 15:40 · Yahoo
CVS Health Corporation (CVS) Hit a 52 Week High, Can the Run Continue?
2026-06-12 13:15 · Yahoo
Strong Performance Continues at DHR's Biotechnology Unit: What's Next?
2026-06-11 15:15 · Yahoo
2 S&P 500 Stocks for Long-Term Investors and 1 Facing Challenges
2026-06-10 13:53 · Yahoo
GENFIT: NASHnext®, Powered by GENFIT's Non-invasive Diagnostic Technology NIS4®, Launched via Labcorp’s OnDemand Offering for Identification of At-Risk MASH
2026-06-08 16:00 · Yahoo
Why Is Pediatrix Medical Group (MD) Down 1.7% Since Last Earnings Report?
2026-06-04 15:30 · Yahoo
Assessing Labcorp (LH) Valuation As Shares Cool And P/E Trails Healthcare Peers
2026-06-02 10:10 · Yahoo
LH Expands Genetic Testing in CRC Through New Collab: Stock to Gain?
2026-06-01 13:11 · Yahoo
3 Cash-Producing Stocks That Concern Us
2026-05-29 15:12 · Yahoo
Labcorp Supports Multi-Institution Trial to Expand Genetic Testing in Colorectal Cancer
2026-05-29 11:00 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.
SEC EDGAR filings → · StockAnalysis.com → · OpenInsider →